PPD Evidera Health Economics

Our Solutions Clinical Development PPD Evidera Health Economics & Market Access PPD Evidera Health Economics

Demonstrate your product’s economic value with advanced modelling and evidence synthesis

Understanding the full value of your product relies on research that illuminates benefits beyond clinical trial data. Stakeholders are also looking for evidence of economic impact and patient outcomes to make informed decisions for regulatory approval and market access. In today’s competitive health care arena, health economics and outcomes research (HEOR) data are no longer supplemental information but are foundational to a product’s ultimate success.

Stand out in a crowded space or demonstrate how your product meets an unmet need in an area with few to no available treatment options for patients. With almost 40 years of experience in health economics, evidence synthesis and value communication, our team enables our clients to differentiate their products from their competitors with health economic evidence such as cost-effectiveness, budget impact and patient experience data, including patient satisfaction, preferences and health outcomes.

Creating the full and persuasive evidence package you need to demonstrate product value requires a confluence of factors, including:

A thorough understanding of and alignment on your product’s key value messages
Convincing underlying economic evidence
Comprehensive strategies to achieve market access
The ability to address the requirements and nuances of individual markets

You can expect credible evidence of the highest quality from our diverse team of scientists, statisticians, modelers and consultants who work collaboratively to understand and address your specific needs. We partner with our clients to develop global and local evidence generation strategies and tactical execution that brings together the right evidence, resonating with all stakeholders, including payors, health technology assessment (HTA) bodies, regulators, health care professionals and patients.

Satisfy your stakeholders while supporting optimal product positioning and differentiation for global success.

Team of professionals reviewing charts, graphs, and data.

Demonstrate product value with credible evidence

Evidence demands continue to change in this dynamic health care environment, requiring increasingly sophisticated methods to demonstrate value. Benefit from a holistic and flexible approach to HEOR and market access studies that adapts to your needs and those of your stakeholders. Partner with our industry-leading experts in evidence synthesis, modeling and simulation, market access, and patient-centered research to:

Provide compelling, actionable evidence at every stage of development to inform decision-making, guide product launch activities and fulfill stakeholder expectations
Unlock the value of published and “grey” literature to build your foundation of evidence
Demonstrate real-world value by simulating expected outcomes that can inform trial design, identify evidence gaps and quantify the economic value of your product
Integrate patient perspectives and preferences with patient experience data to optimize access and uptake
Position and support your value story with persuasive, payor-tested evidence

It can be overwhelming to uncover and transform a multitude of data into evidence to support your asset’s unique value story. Developing a compelling value narrative requires strategy, planning, tactical implementation, the flexibility to adapt to new information, and continual communication to stakeholders. Negotiating the intricate, challenging and complex path to product success and patient access is easier with an experienced and knowledgeable partner.

Modeling and simulation

Harness the power of health economic modeling to demonstrate the value and cost-effectiveness of your products to inform pricing strategies, market access negotiations and health economic evidence generation. Our team works collaboratively with you to understand your end goals and implement the right study design to answer your questions effectively.

With an innovative and tailored approach, we enable clients to:

Quantify the health and economic value of interventions
Estimate the burden of illness and budget impact
Identify evidence gaps within the value story
Estimate comparative effects across therapies
Inform clinical trial design and simulate expected outcomes
Evaluate pricing scenarios
Inform strategic portfolio planning and product development
Support submissions to regulatory agencies and health authorities

Disease simulation

Simulating the effects of an intervention on a specific disease can inform clinical trial design, support commercial strategy development and meet HTA agency requirements for formal submissions. ACE simulators are disease-specific models that are comprehensive, extensively documented and have multiple applications.

Alzheimer’s disease ACE simulator

Assess interventions for Alzheimer’s disease (AD) that span from the earliest (i.e., mild cognitive impairment or prodromal AD) through the most severe stages, and the transition from normal cognitive function. Building on our widely used models in AD, our simulation experts designed the AD ACE to address the complex interactions between multiple components of AD pathology (e.g., biomarkers, cognition, behavior and function) and their roles in disease progression. Fully considering interrelated clinical, epidemiologic and economic outcomes, AD ACE provides a platform for the rapid incorporation of intervention-specific data.

Explore the use of ACE simulators for your therapeutic area of interest

Data,Analytics,And,Insights,Powered,By,Big,Data,And,Artificial

Evidence synthesis

Reduce uncertainty and validate conclusions with synthesized data from multiple study sources. Health economic studies require reliable and robust data inputs to produce trustworthy and actionable results. Evidence synthesis identifies, collects, and analyzes clinical and real-world data from a variety of available sources, providing a comprehensive understanding of treatment effectiveness, safety and cost-effectiveness. By synthesizing evidence from multiple sources, insights can be gleaned and updated at different stages of development.

Understanding the best methodological option for your specific research need is paramount. Whether you need to develop inputs for economic models, explore pricing scenarios or strengthen your overall value development and dissemination, our evidence synthesis experts have the experience to deploy the right solutions, including:

Systematic reviews that involve a rigorous and structured approach to identify, select and critically appraise relevant studies that aim to minimize bias and provide a comprehensive synthesis of the available evidence

Meta-analysis that combines data from multiple studies to provide a quantitative summary of treatment effects, reducing limitations of individual studies and providing more precise estimates of treatment effectiveness

Network meta-analysis (NMA) that extends the scope of traditional meta-analysis by comparing multiple interventions simultaneously, allowing for indirect comparisons among treatments and helping rank interventions based on their relative effectiveness

Scoping reviews that provide a broad overview of existing evidence, mapping the available literature and identifying research gaps, which is particularly valuable when addressing emerging topics or complex research questions

Build a robust foundation for evidence-based decision-making by leveraging advanced evidence synthesis methodologies and expertise to identify unmet therapeutic value, disease burden, epidemiology, comparative effectiveness and budgetary impact.

Targeted approaches to enhance indirect treatment comparisons

Evidence on the relative effectiveness of treatments is rarely available from head-to-head studies and, as a result, published results from clinical trials are often used for indirect treatment comparisons via NMA. However, more novel methods may be needed where standard techniques are inadequate, such as an incomplete or disjointed evidence network, substantial heterogeneity between studies or where the treatments of interest can only be linked through multiple intermediate comparisons.

Simulated treatment comparisons (STC) and matching-adjusted indirect comparisons (MAIC) are powerful tools that can often help to overcome the challenges of NMAs or complement an NMA with a more targeted assessment of the relative effectiveness of the treatments. Increasingly accepted and used by HTA bodies to inform funding and access decisions, STCs and MAICs are becoming more commonly used for indirect comparisons due to the increase in single-arm studies.

Assess the need and suitability of targeted comparisons for your studies by leveraging experts and innovators in indirect comparison approaches. Our team has years of successfully supporting National Institute for Health and Care Excellence submissions where targeted approaches have been applied for indirect comparisons. We provide our clients with scientific and strategic guidance on the right methodology to generate robust evidence of comparative effectiveness, skillful execution of analyses, clear communication of the findings and incorporation into health economic assessments and agency submissions.

Benefit from unmatched experience

0 +

Global experts

0 +

Indications across 15+ therapeutic areas studied

0 +

HTA submissions in the past five years

0 +

Systematic literature reviews in the past five years

0 +

Network meta-analysis (NMA) studies completed in the past five years

0 +

Health economics models and adaptations delivered in the last five years

Health economics plays a crucial role in health care decision making, resource allocation and optimizing patient outcomes. We empower our clients to make informed decisions that prioritize value for investment, improve access to cost-effective treatments, and drive positive changes in drug development and health outcomes.

Move your product forward with effective health economic data that sways stakeholders.